NEUROCRINE BIOSCIENCES INC Goodwill, Foreign Currency Translation Gain (Loss)
NEUROCRINE BIOSCIENCES INC (NBIX) reported Goodwill, Foreign Currency Translation Gain (Loss) of -$100.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Other Income
us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC goodwill, foreign currency translation gain (loss) for the quarter ending 2026-03-31 was -$100.00K.
- NEUROCRINE BIOSCIENCES INC goodwill, foreign currency translation gain (loss) for the quarter ending 2024-12-31 was -$400.00K, a 233.33% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC goodwill, foreign currency translation gain (loss) for the quarter ending 2024-09-30 was $400.00K.
- NEUROCRINE BIOSCIENCES INC goodwill, foreign currency translation gain (loss) for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC goodwill, foreign currency translation gain (loss) for fiscal 2024 was -$100.00K, a 125.00% decline from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC goodwill, foreign currency translation gain (loss) for fiscal 2023 was $400.00K, a 100.00% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC goodwill, foreign currency translation gain (loss) for fiscal 2022 was $200.00K.
| Period end | Goodwill, Foreign Currency Translation Gain (Loss) 3 month | Goodwill, Foreign Currency Translation Gain (Loss) 6 month | Goodwill, Foreign Currency Translation Gain (Loss) 9 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$100.00K 10-Q · filed 2026-07-31 | |||
| 2024-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $0.00 derived: sum of 2 quarters · filed 2025-02-10 | $0.00 derived: sum of 3 quarters · filed 2025-02-10 | -$100.00K 10-K · filed 2025-02-10 |
| 2024-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $400.00K derived: sum of 2 quarters · filed 2024-10-30 | $300.00K 10-Q · filed 2024-10-30 | $600.00K derived: sum of 4 quarters · filed 2025-02-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$100.00K 10-Q · filed 2024-08-01 | $200.00K derived: sum of 3 quarters · filed 2025-02-10 | $0.00 derived: sum of 4 quarters · filed 2025-02-10 |
| 2024-03-31 | -$100.00K 10-Q · filed 2024-05-01 | $200.00K derived: sum of 2 quarters · filed 2025-02-10 | $0.00 derived: sum of 3 quarters · filed 2025-02-10 | $100.00K derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $100.00K derived: sum of 2 quarters · filed 2025-02-10 | $200.00K derived: sum of 3 quarters · filed 2025-02-10 | $400.00K 10-K · filed 2025-02-10 |
| 2023-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | -$100.00K derived: sum of 2 quarters · filed 2023-10-31 | $100.00K 10-Q · filed 2023-10-31 | |
| 2023-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $300.00K 10-Q · filed 2023-08-01 | ||
| 2023-03-31 | $200.00K 10-Q · filed 2023-05-03 | |||
| 2022-12-31 | $200.00K 10-K · filed 2024-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |